A detailed history of Great Lakes Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Great Lakes Advisors, LLC holds 819 shares of VRTX stock, worth $423,210. This represents 0.0% of its overall portfolio holdings.

Number of Shares
819
Previous 1,709 52.08%
Holding current value
$423,210
Previous $801,000 52.56%
% of portfolio
0.0%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$460.0 - $505.78 $409,400 - $450,144
-890 Reduced 52.08%
819 $380,000
Q2 2024

Aug 05, 2024

SELL
$392.81 - $485.53 $983,989 - $1.22 Million
-2,505 Reduced 59.44%
1,709 $801,000
Q1 2024

May 08, 2024

BUY
$407.69 - $446.08 $980,902 - $1.07 Million
2,406 Added 133.08%
4,214 $1.76 Million
Q4 2023

Feb 08, 2024

BUY
$343.0 - $410.68 $620,144 - $742,509
1,808 New
1,808 $735,000
Q3 2021

Nov 09, 2021

SELL
$181.39 - $202.99 $217,849 - $243,790
-1,201 Closed
0 $0
Q2 2021

Aug 11, 2021

BUY
$187.49 - $221.1 $225,175 - $265,541
1,201 New
1,201 $242,000
Q3 2020

Nov 04, 2020

SELL
$255.65 - $303.1 $208,354 - $247,026
-815 Closed
0 $0
Q2 2020

Aug 07, 2020

BUY
$225.48 - $295.8 $183,766 - $241,077
815 New
815 $237,000
Q3 2019

Nov 06, 2019

SELL
$166.23 - $187.09 $214,270 - $241,159
-1,289 Closed
0 $0
Q2 2019

Aug 05, 2019

SELL
$164.61 - $190.37 $164,774 - $190,560
-1,001 Reduced 43.71%
1,289 $236,000
Q1 2019

May 07, 2019

BUY
$163.73 - $194.7 $120,014 - $142,715
733 Added 47.08%
2,290 $421,000
Q4 2018

Feb 13, 2019

SELL
$151.91 - $192.21 $18,229 - $23,065
-120 Reduced 7.16%
1,557 $258,000
Q3 2018

Nov 30, 2018

BUY
$167.73 - $192.74 $281,283 - $323,224
1,677 New
1,677 $323,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $133B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Great Lakes Advisors, LLC Portfolio

Follow Great Lakes Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Lakes Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Great Lakes Advisors, LLC with notifications on news.